Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: A phase II trial of the sarah cannon oncology research consortium

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 267-272

  Hainsworth, John D ^a,b   Spigel, David R ^a,b   Greco, F Anthony ^a,b   Shipley, Dianna L ^a,b   Peyton, James ^a,b   Rubin, Mark ^a,c   Stipanov, Michael ^a,d   Meluch, Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Florida Cancer Specialists   (United States)

^d Chattanooga Oncology Hematology Associates   (United States)

Author keywords

bevacizumab; Combined modality therapy; erlotinib; locally advanced head and neck cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; FLUOROURACIL; PACLITAXEL;

ACNE; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; MUCOSITIS; NEOADJUVANT THERAPY; NEUTROPENIA; PACLITAXEL; QUINAZOLINES;

EID: 80053352822     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182329791     Document Type: Article

References (25)

1. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955. (Pubitemid 30148259)
2. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645. (Pubitemid 46211506)
3. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-1715. (Pubitemid 350005152)
4. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85. (Pubitemid 41095117)
5. Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-1987. (Pubitemid 46606387)
6. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-8654. (Pubitemid 46211507)
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
8. Reidel F, Gotte K, Schwalb J, et al. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol. 2000;257:332-336. (Pubitemid 30612326)
9. Smith BD, Smith GL, Carter D, et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18:2046-2052. (Pubitemid 30324357)
10. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378. (Pubitemid 29334495)
11. Woehsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents. Exploring mechanisms of interaction. Clin Cancer Res. 2003;9:1957-1971. (Pubitemid 36687614)
12. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26:1732-1741.
13. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756. (Pubitemid 19272848)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
15. Hainsworth JD, Meluch AA, McClurkan S, et al. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J. 2002;8:311-321.
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http://ctep.cancer.gov). Publish date: August 9, 2006.
17. Bernier J, Domeyee C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952. (Pubitemid 38580197)
18. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
19. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advancedstage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76. (Pubitemid 41095116)
20. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol. 2006;24: 1064-1071. (Pubitemid 46638803)
21. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2009; 28:8-14.
22. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28:43-48.
23. Wanebo HJ, Ghebremichael MS, Burtness B, et al. Phase II induction cetuxumab (C225), paclitaxel (P) and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72 Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG E2303). J Clin Oncol. 2010;28:424s. Abstract 5513.
24. Ferris RL, Heron DE, Kim S, et al. Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): mature results with HPV analysis. J Clin Oncol. 2010;28:424s. Abstract 5515.
25. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.